DSIP (Delta Sleep-Inducing Peptide) for Sleep Quality — Brain
Neuropeptide for sleep architecture normalization. Small 1980s human trials. NOT a sedative. NOT FDA-approved.
Overview
DSIP (Delta Sleep-Inducing Peptide) is a 9-amino acid neuropeptide first isolated in 1974 from rabbit brain. CRITICAL DISTINCTION: DSIP is NOT a sedative — it normalizes sleep architecture by promoting delta (slow-wave) sleep via NMDA receptor modulation, rather than inducing unconsciousness. EVIDENCE STATUS: Small human trials from the 1980s showed objective polysomnographic improvement in insomniacs (increased slow-wave sleep, reduced latency, fewer arousals, increased REM). However, sample sizes were small (<15 subjects per study) and no large RCTs exist. DSIP also shows stress-protective properties (lowers basal corticotropin, modulates CRF pathways) and preliminary evidence for opioid/alcohol withdrawal symptom relief. SHORT HALF-LIFE (~15 min plasma) but may bind carrier proteins in vivo for extended effects. The 2001 European Journal of Anaesthesiology editorial described DSIP as "incredibly safe" with no lethal dose found in animal studies. NOT FDA-approved. Available only as research peptide.
Indications
- Insomnia and sleep quality improvement (small clinical trials - polysomnographic improvement)
- Delta (slow-wave) sleep promotion - increased REM and deep sleep stages
- Sleep architecture normalization (NOT sedation - does not induce unconsciousness)
- Stress and anxiety reduction (modulates CRF pathways, lowers corticotropin)
- Opioid withdrawal symptom relief (97% reported relief in one trial of ~100 patients)
- Alcohol withdrawal support (87% reported symptom relief)
- Chronic pain (one 1984 pilot study - weak evidence)
- Stroke recovery (preclinical rodent data - neuroprotection and motor recovery)
Mechanism of Action
Insomnia, chronic stress, or substance withdrawal disrupts normal sleep patterns — reducing slow-wave (delta) sleep and REM stages, increasing nighttime arousals
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| DSIP | 100-300 mcg | Once daily, 30-90 min before bedtime | Standard starting dose. Extrapolated from IV clinical data. No formal SC trials exist. |
| DSIP | 300-500 mcg | Once daily or 3-5x/week before bed | Advanced dose for severe insomnia. Effects may persist multiple nights. |
Evidence Grade
GRADE D
Safety & Contraindications
- CRITICAL: NOT FDA-approved in any country
- No lethal dose found in animal studies
- Mild transient side effects: headache, nausea, vertigo
- SC injection: mild site reactions (redness, irritation)
- Long-term safety UNKNOWN - most clinical trials lasted less than 2 weeks
- Short plasma half-life (~15 min) requires consistent dosing
- Quality/purity highly variable from research peptide vendors
- Contraindicated in severe psychiatric disorders
- Avoid in untreated sleep apnea
- No data for pregnancy/lactation
- Potential additive CNS effects with sedatives and alcohol
- WADA status: not explicitly banned but future scrutiny possible